Ocumension Therapeutics (1477.HK)
Develops eye disease medications for the Chinese market.
5.06-0.06%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-46.3%
The outlook
Ocumension Therapeutics trades at 5.06, sitting well below both its 50- and 200-day moving averages, positioning it near the lower end of its 52-week range. Analyst coverage is thin with just two Buy ratings, and their average price target sits roughly 89% above the current price. The overall data suggests a depressed stock with bullish analyst sentiment, though the price trend remains weak.
What’s behind the score
Analyst consensusBuy — 2.0 avg of 2 analysts
Price trendBelow its 50- & 200-day averages
52-week range12% of the way from its 52-week low to high
Price targetAvg target +89% vs current price
Analyst price target
~12-month · 2 analysts9.57average target+89.1% vs now
Now 5.06
Low 8.81High 10.32
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$4.07B
52-wk high
12.23
52-wk low
4.04
50-day avg
5.44
200-day avg
7.10
Trailing P/E
—